A systematic review of rubella vaccination strategies implemented in the Americas: impact on the incidence and seroprevalence rates of rubella and congenital rubella syndrome

Mongua-Rodríguez, Norma; Díaz-Ortega, José Luis; García-García, Lourdes; Piña-Pozas, Maricela; Ferreira-Guerrero, Elizabeth; Delgado-Sánchez, Guadalupe; Ferreyra-Reyes, Leticia; Cruz-Hervert, Luis Pablo; Baéz‐Saldaña, Renata; Campos-Montero, Rogelio

doi:10.1016/j.vaccine.2013.02.047

Cited by 26 publications

(17 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…With continuing circulation of rubella virus, there is a persistent risk of infection in susceptible pregnant women, even when only 2% – 3% of pregnant women are non-immune [9]. The circulation of rubella virus can occur in the presence of a low vaccination coverage rate in some populations in the community [10-12], as was confirmed in the current outbreak in Japan. The principal rationale for an accelerated vaccination strategy is to reduce the time needed to interrupt rubella virus circulation and to prevent CRS [13].…”

Section: Discussionmentioning

confidence: 95%

“…Samuel and John [14] stated that “To eliminate CRS, virus transmission should be interrupted.” Our data combined with those obtained in the serosurvey and the current outbreak strongly suggest that more intensified universal vaccination programs targeting adolescents and children are required and that supplementary immunization activity should be focused on male adults to interrupt endemic rubella transmission. Programs to eliminate rubella have indeed been successful in the USA [15] and appear to have been successful in some European countries [16] and the Americas [12]. It is necessary to realize that “Treatment of CRS is costly and rubella vaccination programs are highly cost-effective” [17].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effects of campaign for postpartum vaccination on seronegative rate against rubella among Japanese women

et al. 2014

View full text Add to dashboard Cite

BackgroundJapan experienced two rubella outbreaks in the past decade (2004 and 2012 – 2013), resulting in 10 and 20 infants with congenital rubella syndrome (CRS), respectively. This study was performed to determine whether the seronegative rate was lower in multiparous women than in primiparous women in Japan.MethodsHemagglutination inhibition (HI) test results during pregnancy were analyzed retrospectively in 11048 primiparous and 9315 multiparous women who gave birth at six hospitals in northern Japan in the 5-year study period (January 2008 through December 2012). Women with HI titer < 1:8 were defined as susceptible to rubella.ResultsThe seronegative rate was significantly lower in multiparous than primiparous women aged 30 – 31 years (2.3% [22/967] vs. 4.5% [66/1454], P = 0.0036), 36 – 37 years (3.4% [55/1601] vs. 5.7% [79/1389], P = 0.0030), and overall women (3.8% [350/9315] aged 34.7 ± 5.2 vs. 5.4% [597/11048] for 33.2 ± 5.9, P < 0.001). The susceptible fraction size did not differ largely according to hospital, ranging from 3.5% to 6.3%. Those for each year did not change markedly; 4.5% [150/3369], 5.2% [221/4268], 4.4% [195/4412], 4.6% [186/4056], and 4.6% [195/4258] for 2008, 2009, 2010, 2011, and 2012, respectively. Those for teenagers were consistently high: 22.7% [5/22], 20.7% [6/29], 20.6% [7/34], 13.0% [3/23], and 23.5% [4/17] for 2008, 2009, 2010, 2011, and 2012, respectively.ConclusionsThe seronegative rate was significantly lower in multiparous than primiparous women. However, Japanese rubella vaccination programs were insufficient to eliminate CRS.

show abstract

Section: Discussionmentioning

confidence: 95%

Section: Discussionmentioning

confidence: 99%

Effects of campaign for postpartum vaccination on seronegative rate against rubella among Japanese women

et al. 2014

View full text Add to dashboard Cite

show abstract

“…The age and dose of the Rubella vaccination may vary depending on a country’s vaccination policy. In general, an 84.7% seropositivity rate is achieved by single-dose vaccination, and this rate reaches 90% with two doses of vaccine (ages 1 and 5) (16) . In our country, Rubella vaccines are administered as two doses in children at 12 months and 7 years.…”

Section: Discussionmentioning

confidence: 99%

“…Turkey’s neighboring Iran has a seropositivity rate of 94%, (17) and Greece, which is a member of the European Union, has a seropositivity rate of 97% in women with childbearing age (18) . This ratio is 89.3% in Brazil and 99.3% in the United States of America (16) . In India, which is a Far East country, it is 68.3%.…”

Section: Discussionmentioning

confidence: 99%

The seroprevalence of Rubella in pregnant women in Turkey: a meta-analysis research of 90988 Rubella IgM, 84398 Rubella IgG, and 522 avidity results

Çeti̇nkaya

Yeni̇lmez

2019

tjod

View full text Add to dashboard Cite

Objective: Rubella infection prevalence in pregnant women can vary from country to country, or even across regions in the same country. In this metaanalysis, the seroprevalence Rubella among pregnant women in Turkey in the last decade was evaluated. Materials and Methods: Studies conducted in Turkey between 2007 and 2017 were analyzed, and differences in seroprevalence between provinces were compared by evaluating Rubella immunoglobulin (Ig)-G, IgM, and IgG avidity results in pregnancy in this period. A data search was performed using the search terms Rubella, kızamıkçık, gebe, hamile, pregnancy, Türkiye, Turkey in Google Scholar, PubMed, Web of Science, Türk Medline, and the YÖK thesis database center. Results: A total of 26 articles associated with the seroprevalence of Rubella among pregnant women in Turkey were enrolled in the meta-analysis. As a result of an analysis of 84398 Rubella IgG, and 90988 Rubella IgM serology tests among pregnant women in 26 studies; Rubella IgG and IgM seroprevalence rates in pregnant woman in Turkey were found as 93.47% (95% CI: 91.72 to 95.03) and 0.783% (95% CI: 0.505 to 1.120), respectively. Rubella IgG low, intermediate, and high avidity rates were 4.66% (95% CI: 0.969 to 10.906), 7.51% (95% CI: 5.101 to 10.345), and 93.55% (95% CI: 82.584 to 99.311), respectively. Conclusion: The Rubella IgG seropositivity rate in Turkey among pregnant woman is high, whereas it is low for IgM. These rates may be considered as the result of successful immunization policies and practices. In a few provinces, it is necessary to revise the Rubella immunization procedures and adult vaccination strategies should be developed in order to control Rubella infections in adults, including pregnant women.

show abstract

“…From 1998 to 2005, vaccination campaigns were carried out in Chile, Brazil, Costa Rica, Honduras, Ecuador and El Salvador; another 18 countries were added in subsequent years. The campaigns had a huge impact on measles as well as preventing the re‐establishment of endemic measles virus transmission in the region .…”

Section: Case Studiesmentioning

confidence: 99%

Role of vaccine manufacturers in developing countries towards global healthcare by providing quality vaccines at affordable prices

Jadhav

Gautam

Gairola

2014

Clinical Microbiology and Infection

View full text Add to dashboard Cite

Vaccines represent one of the greatest achievements of science and medicine in the fight against infectious diseases. Vaccination is one of the most cost-effective public health tools to prevent infectious diseases. Significant progress has been made in expanding the coverage of vaccines globally, resulting in the prevention of more than two million deaths annually. In 2010, nearly 200 countries endorsed a shared vision to extend the benefits of vaccines to every person by 2020, known as the Decade of Vaccine Initiative (DoV). Vaccine manufacturers in developing countries, as represented by the Developing Countries Vaccine Manufacturers Network (DCVMN), make a significant contribution to DoV by supplying quality vaccines at affordable prices to the people who need them most. About 70% of the global Expanded Program on Immunization (EPI) vaccine supplies are met by DCVMN. Besides EPI vaccine supplies, DCVMN is also targeting vaccines against rotavirus, Japanese encephalitis, pneumonia, human papillomavirus, meningitis and neglected tropical diseases. This article reviews the roles and contributions of DCVMN in making the vaccines accessible and affordable to all.

show abstract

A systematic review of rubella vaccination strategies implemented in the Americas: impact on the incidence and seroprevalence rates of rubella and congenital rubella syndrome

Cited by 26 publications

References 27 publications

Effects of campaign for postpartum vaccination on seronegative rate against rubella among Japanese women

Effects of campaign for postpartum vaccination on seronegative rate against rubella among Japanese women

The seroprevalence of Rubella in pregnant women in Turkey: a meta-analysis research of 90988 Rubella IgM, 84398 Rubella IgG, and 522 avidity results

Role of vaccine manufacturers in developing countries towards global healthcare by providing quality vaccines at affordable prices

Contact Info

Product

Resources

About